Stay updated with breaking news from All Immatic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics' proprietary CD8aß co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inhibitor